ClinicalTrials.gg
TerminatedNCT03624608Updated Jan 23, 2025

Evaluation of the Auryzon Devices in the Optimization of Ear and Nose Reconstruction Procedures

An interventional study of AuryzoN Family of Devices in Ear Deformities, Acquired, Ear; Deformity, Congenital and Microtia, sponsored by Reconstrata, LLC. Terminated at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-01-23.

Primary conditionCongenital Abnormalities(the registry's first term)UnverifiedIs this wrong?Congenital Abnormalities is a broad heading, used only when no more specific condition is named. No better condition is named, so the registry's term is kept.

Sponsored by Reconstrata, LLC · Not applicable, Interventional, and Treatment

How we know

Why this study was terminated
Enrollment target not reached.

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 10 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2
Allocation
Not applicable
Sex
All
01

Study summary

This study evaluates the efficacy of the AuryzoN devices in the ear and nose reconstruction surgeries, both in terms of operative time and overall quality of reconstruction. Research participants will undergo reconstruction either using the AuryzoN device or through current methods (traditional manual processing) at the discretion of their surgeon prior to the start of surgery.

Read the detailed description

The AuryzoN devices are a family of two (2) devices that, in conjunction, serve to process substrates of autologous-derived or cadaveric cartilage used in the reconstruction of various structures of the body, namely ear and nose. The devices are to be used in the operating room to cut and carve substrates of tissue into components, which are then assembled into the final ear or nose, that will then be implanted by the plastic surgeon into the appropriate area. This device family serves to replace the current step in this reconstructive procedure, which involves the time-consuming and error-prone process of manual cartilage processing.

Participants will be given the option to participate in the study. If the participants so choose, they will undergo ear or nose reconstruction using the AuryzoN devices or traditional manual processing at the discretion of their surgeon prior to the start of surgery. The following outcome measures will be measured: operative time, error rates, objective quality outcomes of reconstruction, subjective quality outcomes of reconstruction, and patient satisfaction.

02

Conditions studied

  • Ear Deformities, Acquired
  • Ear; Deformity, Congenital
  • Microtia
  • Nose Deformity
  • Nose Deformities, Acquired
  • Nose; Deformity, Congenital
  • Nose; Deformity, Congenital, Bent or Squashed
  • Nose; Deformity, Syphilitic, Congenital
  • Nose; Deformity, Bone (Nose Cartilage)
  • Nose; Deformity, Septum, Congenital
  • Nose; Deformity, Sinus (Wall), Congenital
  • Nose; Deformity, Syphilitic, Late (Etiology)
  • Ear; Deformity, External
  • Ear; Deformity, Auricle, Ear, Acquired
  • Ear; Deformity, Auricle, Ear (Congenital)
03

In context

Congenital Abnormalities Unverified

782 studies on the registry are indexed under Congenital Abnormalities; 78 are open to participants now.

This study's enrollment of 2 is below the median of 40 across 466 interventional studies indexed under Congenital Abnormalities.

Browse Congenital Abnormalities studies →

Lead sponsor

This is the only study on the registry with Reconstrata, LLC as lead sponsor.

Compared within Congenital Abnormalities, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 1-100 of sufficient health required to undergo ear/nose reconstruction under general anesthesia
  • Pre-existing physical deformity of the ear, nose, or eyelid necessitating surgical reconstruction
  • Sufficient autologous or cadaveric rib cartilage for use by the AuryzoN system for cartilage processing

Exclusion criteria

Exclusion Criteria:

  • Patients with ear/nose/eyelid deformities not requiring surgical correction
  • Patients without sufficient rib cartilage for use by the AuryzoN system and those who do not desire cadaveric cartilage use
  • Patients in poor health to undergo surgery under general anesthesia
  • Patients whose desired ear/nose/eyelid exceeds the dimensions/shapes of those pre-fabricated blades used in the AuryzoN system
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2 participants (actual)

Study arms

  • Experimental
    Auryzon-Processed Ear/Nose

    Patients in this category underwent reconstruction and implantation of a completed ear/nose cartilaginous graft that was processed using the AuryzoN device.

    Device: AuryzoN Family of Devices

Interventions

  • DeviceAuryzoN Family of Devices

    The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).

06

What researchers measure

Primary outcomes

  1. Total cartilage processing time

    Total operative time spent by the surgeon preparing cartilage substrate into finished structures

    Time frame: Three years (until 2023)

  2. Objective Quality of Reconstruction

    An objective scoring system will be developed to score ears and noses based on anatomic accuracy, and reconstructed ears/noses will be scored using this system. Scoring system scale: The following metrics will be assessed by independent observers on a scale from 0-5, with 5 indicating perfect anatomic fidelity as compared to the patient's contralateral ear (or a model ear if no contralateral ear is available) or model nose and 0 indicating complete anatomical difference or loss of that structure. The following ear and nose subcomponents will be graded: Ear: Helix, antihelix, tragus, crus, anatomical proportion of all substrates as compared to each other substrate. Nose: Septum, alar cartilages, lateral cartilages, horizontal strut, anatomical proportion of all substrates as compared to each other substrate.

    Time frame: Up to 1 year post-op (until 2023)

Secondary outcomes

  1. Total operative time

    Total operative time by the surgeon performing the reconstructive surgery

    Time frame: Three years (until 2023)

  2. Cartilage processing error rate

    Number of errors (defined as anatomic deviations) incurred during cartilaginous processing

    Time frame: Three years (until 2023)

  3. Patient satisfaction

    Subjective survey completed by patients asking about satisfaction with reconstruction

    Time frame: Up to 1 year post-op (until 2023)

  4. Subjective Quality of Reconstruction

    Images of completed ear/nose reconstructions with the AuryzoN system will be presented to surgeons and lay-people to determine overall subjective quality of reconstruction

    Time frame: Up to 1 year post-op (until 2023)

07

Study locations

1 site
  • Cincinnati Children's Hospital
    Cincinnati, Ohio 45229, United States
08

References and documents

Publications

  • Leto Barone AA, Arun A, Samaha GJ, Shallal CC, Redett RJ, Steinberg JP. Design of a Novel Reproducible Cartilage-Sparing Autologous Technique for Microtia Repair. Facial Plast Surg Aesthet Med. 2021 May-Jun;23(3):224-229. doi: 10.1089/fpsam.2020.0457. Epub 2020 Nov 12. PubMed 33185490 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Jan 2025, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2018
First posted
Aug 10, 2018
StartActual
Mar 1, 2020
Primary completionActual
Jan 20, 2025
CompletionActual
Jan 20, 2025
Last update
Jan 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03624608
Lead sponsor
Reconstrata, LLC
Responsible party
Sponsor
First posted
Aug 10, 2018
Start date
Mar 1, 2020
Primary completion
Jan 20, 2025
Completion
Jan 20, 2025
Last update
Jan 23, 2025

Study contacts

Angelo Leto Barone
principal investigator · Reconstrata, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion